If you follow longevity science for long enough, you develop a healthy reflex: when a supplement is hailed as anti-aging, assume it will disappoint under proper scrutiny. Most do. So it's worth paying attention when one of the oldest, cheapest, least glamorous supplements on the shelf — fish oil — quietly did something in a rigorous trial that almost nothing else has managed: it slowed a validated measure of biological aging. That doesn't make it a miracle. But it does make omega-3 one of the few longevity supplements whose story rests on human trials rather than hopeful extrapolation from mice.
What omega-3 fatty acids actually are
“Omega-3” is a family, not a single molecule. The two that matter most for health are EPA (eicosapentaenoic acid, chemical formula C20H30O2) and DHA (docosahexaenoic acid, C22H32O2), both long-chain fatty acids found mainly in oily fish like salmon, sardines and mackerel. A third, shorter one — ALA, from plants such as flaxseed and walnuts — your body can only convert into EPA and DHA very inefficiently, which is why fish (or algae, for vegans) is the reliable source.
These aren't just fuel. EPA and DHA get physically built into the membranes of your cells, where they change how flexible those membranes are and how cells signal to one another. DHA is especially concentrated in the brain and the retina. And crucially for aging, omega-3s are the raw material your body uses to make specialised molecules that actively switch off inflammation once it's done its job. That anti-inflammatory role is a recurring thread in almost everything omega-3 seems to do.
The trial that moved an aging clock
To understand why the recent result mattered, you need to know what an “aging clock” is. Over the past decade, scientists have learned to estimate a person's biological age — as opposed to their birthday age — by reading chemical tags called methylation marks on their DNA. The newest of these clocks, with names like PhenoAge, GrimAge and DunedinPACE, are trained to predict health, disease and mortality, and they've become the leading tools for testing whether an intervention actually slows aging rather than just improving how you feel.
The DO-HEALTH trial put omega-3 to that test. Researchers followed 777 older adults for three years, randomly assigning them to take vitamin D (2,000 IU/day), omega-3 (1 g/day), a home exercise programme, various combinations, or none of these. Then they measured four next-generation methylation clocks. The headline finding: omega-3 on its own slowed several of the clocks — PhenoAge, GrimAge2 and DunedinPACE — and when omega-3, vitamin D and exercise were combined, the benefit on PhenoAge stacked up further. Across the board, the effects translated to roughly three to four months of reduced biological aging over the three years.[1]
Let's be honest about the size of that. Three to four months over three years is a small effect, it came from a secondary analysis of the trial rather than its original main goal, and slowing a methylation clock is not the same as proven extra years of healthy life. But hold it against the field: this is one of the only times a cheap, widely available supplement has moved a validated aging clock in a randomised, placebo-controlled human trial at all. Small and real beats large and imaginary. And the fact that vitamin D and exercise added to the effect fits a sensible picture in which no single lever does everything.
The older clue: telomeres
The DO-HEALTH result didn't come out of nowhere. More than a decade earlier, a study had hinted at the same theme using a completely different marker of biological age: telomeres, the protective caps on the ends of your chromosomes that shorten as cells divide and age. Researchers following outpatients with stable heart disease measured omega-3 blood levels at the start and telomere length five years later. Those with the lowest omega-3 levels had the fastest telomere shortening; those with the highest had the slowest. Each standard-deviation increase in EPA plus DHA was associated with about a 32 percent lower odds of rapid telomere loss.[3]
A single observational study can't prove causation — people with high omega-3 levels differ in other ways too. But two independent markers of biological aging, telomeres in 2010 and methylation clocks in 2025, pointing the same direction is a more convincing pattern than either alone. It suggests the omega-3 signal is picking up something real about the pace of aging, not a fluke of one measurement method.
Why the heart evidence is the real foundation
Strip away the aging-clock excitement and omega-3's sturdiest evidence is cardiovascular — and that matters, because heart disease remains the single biggest thing standing between most people and a long life. Two threads stand out. The first is mechanism you can measure. A large meta-analysis of 48 randomised trials in more than 8,000 people found that omega-3 supplementation reliably lowered triglycerides, modestly reduced blood pressure, and brought down several markers of inflammation — including IL-6, TNF-α and C-reactive protein. Interestingly, the review found doses at or below 2 grams a day gave the best overall balance of benefit, a useful corrective to the “more is better” instinct.[4] A separate analysis of 51 trials showed omega-3 also gently slows resting heart rate, an effect driven mainly by DHA.[5]
The second thread is the hardest outcome of all: death. In the Framingham Heart Study — one of the longest-running cohorts in medicine — researchers used the Omega-3 Index, a measure of how much EPA and DHA sits in your red blood cell membranes, to gauge long-term omega-3 status. People in the highest index group had about a 34 percent lower risk of dying from any cause, and a 39 percent lower risk of developing cardiovascular disease, than those in the lowest.[2] That's an association, not proof, and people with high omega-3 levels tend to live healthier in general. But it's a large, consistent signal, and it dovetails with the mechanistic trial data rather than contradicting it.
Where the hype outruns the data: the brain
Honesty cuts both ways, and omega-3's most oversold claim is cognitive. Because DHA is so abundant in the brain, it's intuitive that topping it up should protect memory and stave off dementia — and observational studies linking fish eaters to lower dementia risk keep that hope alive. But when you look at the randomised trials, the picture falls apart. A scoping review of omega-3 supplement trials and cognition found the results frankly inconsistent: some hints of benefit, plenty of null findings, and no clear, reliable effect on preventing cognitive decline in the general older population.[6]
This is exactly the kind of gap between observation and trial that should make anyone cautious. It may be that omega-3 helps only certain subgroups — people who start out deficient, or carry particular genetic risk — or that you need to start much earlier in life than these trials began. Whatever the reason, the current honest answer is that you shouldn't take fish oil expecting to protect your memory. The heart evidence is real; the brain evidence is not there yet.
How to actually get it
The least controversial advice is also the oldest: eat oily fish two or three times a week. That delivers EPA and DHA in a food matrix alongside protein and other nutrients, and it's what most of the positive population data is built on. If you don't eat fish, an algae-based supplement gives vegans and vegetarians a direct source of DHA and EPA without the fish.
If you choose capsules, the trials that showed benefit generally used around 1 to 2 grams a day of combined EPA and DHA — and remember that the number on the front of a fish-oil bottle (“1,000 mg fish oil”) is usually much larger than the actual EPA+DHA content listed on the back, which is what counts. More is not automatically better; the cardiovascular meta-analysis suggested the sweet spot sits at or below 2 grams a day.[4] One genuine caution: omega-3 has a mild blood-thinning effect, so if you're on anticoagulant medication or heading for surgery, talk to your doctor before supplementing.
An honest verdict
Omega-3 is that rare longevity supplement whose case doesn't depend on wishful thinking. In a real three-year trial it modestly slowed validated aging clocks; an older study showed the same direction using telomeres; and underneath sits a deep, consistent body of evidence that it improves cardiovascular risk factors, lowers inflammation, and tracks with lower mortality. That's a genuinely strong hand by supplement standards. The honest caveats are just as important: the aging-clock effect is small, much of the mortality data is observational, and the popular brain-protection claim is not supported by the trials. Set your expectations to “a well-evidenced, low-risk nudge in the right direction,” not “anti-aging breakthrough,” and omega-3 earns its place — ideally from a plate of fish first, and a capsule second.
Common questions
Does omega-3 really slow aging?
In the DO-HEALTH trial, 1 gram of omega-3 a day for three years modestly slowed several next-generation DNA-methylation aging clocks, and combining it with vitamin D and exercise added a little more benefit. The effect was small — on the order of a few months of biological age over three years — but it is one of the few times a cheap supplement has measurably moved a validated aging clock in a randomised trial. It is a promising signal, not a fountain of youth.
How much omega-3 should I take, and from food or capsules?
Oily fish two to three times a week is the best-evidenced source and delivers omega-3 alongside protein and other nutrients. If you use a supplement, most trials showing benefit used roughly 1 to 2 grams a day of combined EPA and DHA, and one review found doses at or below 2 grams a day gave the best overall balance. Higher is not automatically better. Check with a clinician if you take blood thinners.
What is the Omega-3 Index and why does it matter?
The Omega-3 Index measures the amount of EPA and DHA in your red blood cell membranes, giving a longer-term picture of your omega-3 status than a single blood draw. In the Framingham Heart Study, people with a higher index had substantially lower risk of dying from any cause and of developing cardiovascular disease over follow-up. A target above about 8 percent is often suggested, versus under 4 percent being considered low.